Your browser is no longer supported. Please, upgrade your browser.
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own0.13% Shs Outstand19.43M Perf Week0.70%
Market Cap57.00M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float17.47M Perf Month-12.23%
Income-34.90M PEG- EPS next Q-0.46 Inst Own49.30% Short Float13.66% Perf Quarter76.07%
Sales- P/S- EPS this Y54.10% Inst Trans2.62% Short Ratio0.36 Perf Half Y-54.44%
Book/sh2.54 P/B1.13 EPS next Y65.70% ROA-65.00% Target Price- Perf Year-44.91%
Cash/sh- P/C- EPS next 5Y- ROE-73.70% 52W Range1.25 - 8.59 Perf YTD34.11%
Dividend- P/FCF- EPS past 5Y31.70% ROI- 52W High-66.59% Beta1.86
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low129.60% ATR0.44
Employees27 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)45.57 Volatility8.43% 9.24%
OptionableYes Debt/Eq0.00 EPS Q/Q0.20% Profit Margin- Rel Volume0.28 Prev Close3.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume6.60M Price2.87
Recom3.00 SMA20-11.96% SMA501.59% SMA200-38.90% Volume1,849,882 Change-6.82%
Nov-02-20Downgrade Wedbush Outperform → Neutral
Oct-27-20Downgrade Oppenheimer Outperform → Perform
Oct-27-20Downgrade H.C. Wainwright Buy → Neutral
Oct-01-20Initiated H.C. Wainwright Buy $24
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Mar-02-21 08:00AM  
Jan-29-21 10:46AM  
Dec-03-20 08:56AM  
Dec-02-20 08:38PM  
Nov-12-20 04:10PM  
Oct-28-20 07:41AM  
Oct-27-20 08:24AM  
Oct-26-20 05:00PM  
Sep-28-20 08:00AM  
Sep-23-20 08:00AM  
Sep-21-20 08:00AM  
Sep-10-20 08:51AM  
Sep-08-20 08:00AM  
Sep-03-20 08:41AM  
Sep-02-20 08:00AM  
Aug-25-20 08:38AM  
Aug-21-20 10:35AM  
Aug-10-20 04:10PM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-27-20 08:00AM  
Jul-15-20 08:00AM  
Jun-29-20 04:10PM  
Jun-15-20 08:16PM  
Jun-12-20 08:00AM  
May-12-20 04:10PM  
May-07-20 09:30AM  
Apr-28-20 08:00AM  
Apr-17-20 08:00AM  
Mar-27-20 03:22AM  
Mar-25-20 08:00AM  
Mar-24-20 04:00PM  
Mar-18-20 08:00AM  
Mar-14-20 09:32AM  
Mar-10-20 08:05AM  
Feb-25-20 08:00AM  
Feb-21-20 08:00AM  
Feb-03-20 04:05PM  
Jan-30-20 09:00AM  
Jan-29-20 04:01PM  
Jan-09-20 04:09PM  
Jan-08-20 08:00AM  
Dec-24-19 06:15AM  
Dec-23-19 02:15PM  
Dec-16-19 08:00AM  
Nov-25-19 06:45PM  
Nov-18-19 06:53AM  
Nov-07-19 08:05AM  
Oct-24-19 08:00AM  
Oct-19-19 09:26AM  
Oct-18-19 08:00AM  
Oct-05-19 08:00AM  
Sep-30-19 04:05PM  
Sep-27-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-19-19 10:13AM  
Aug-20-19 10:58AM  
Aug-09-19 05:04PM  
Aug-08-19 08:05AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-25-19 08:30AM  
Jul-15-19 03:08PM  
Jun-27-19 08:00AM  
Jun-21-19 09:45AM  
Jun-18-19 08:00AM  
Jun-07-19 09:24AM  
May-15-19 06:33PM  
May-14-19 08:05AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-26-19 03:26PM  
Apr-12-19 11:34AM  
Apr-01-19 08:00AM  
Mar-26-19 12:11PM  
Mar-19-19 12:26PM  
Mar-18-19 09:02AM  
Mar-14-19 06:09PM  
Mar-13-19 08:00AM  
Mar-08-19 09:54AM  
Mar-07-19 08:57AM  
Mar-06-19 01:56PM  
Feb-28-19 08:00AM  
Feb-19-19 08:00AM  
Feb-14-19 08:00AM  
Feb-06-19 09:00AM  
Feb-05-19 04:01PM  
Jan-29-19 07:55AM  
Jan-15-19 11:10AM  
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.